Search

Selective Reduction of Cysteine Residues in IL-17 Antibodies

The European Patent Office published patent application EP3237445A1 by Novartis AG, covering methods for the selective reduction of cysteine residues in IL-17 antibodies. The application names HEITZMANN, Markus and WINKLER, Johann as inventors, with international patent classification codes C07K 16/24 and A61K 39/395. This A1 publication includes the European search report and designates all EU member states plus Switzerland, Norway, and other European Economic Area countries.

Novartis Pharmaceutical Administration System, EPO Patent

The European Patent Office published patent application EP3596635A1, filed by Novartis AG, titled 'System for Administering a Pharmaceutical Product.' The patent covers pharmaceutical administration technology including drug delivery devices and related systems, classified under multiple IPC codes spanning G16H (health informatics), A61M (medical devices), and related categories. The patent is granted with designation across 34 European Patent Convention contracting states.

Acting AG Davenport Files Multistate Complaint Against Novartis and Sandoz Alleging Generic Drug Price Fixing

Acting New Jersey Attorney General Jennifer Davenport and the Division of Consumer Affairs filed a multistate antitrust complaint with 42 states and territories against Novartis AG and its generic subsidiaries Sandoz AG and Sandoz Group AG. The complaint alleges a systemic conspiracy to fix prices, allocate markets, and rig bids for 31 different generic drugs, driving up prescription drug costs for consumers, Medicare, and Medicaid. The complaint also alleges Novartis fraudulently transferred assets from Sandoz to shield itself from liability in three prior antitrust complaints.

PhRMA v. McCuskey — Affirmed: West Virginia Drug Pricing Law Preempted

The Fourth Circuit affirmed the district court's preliminary injunction against West Virginia's S.B. 325, a statute that imposed additional conditions on drug manufacturers participating in the federal 340B program. The court held that S.B. 325 is likely preempted by federal law because it impermissibly reshapes the contractual bargain Congress made with manufacturers under its spending power — requiring manufacturers to provide additional discounts to 340B-covered entities as a condition of their federal program participation. The ruling preserves the existing 340B pricing structure and prevents states from independently expanding manufacturer obligations under the program.

PhRMA v. Maryland - Fourth Circuit Vacates Preliminary Injunction Denial Regarding State 340B Drug Pricing Restrictions

The Fourth Circuit vacated the District Court for the District of Maryland's denial of a preliminary injunction in consolidated cases 24-1949 and 24-1978, remanding for reconsideration. The appeals involved pharmaceutical manufacturers Novartis, Allergan, AstraZeneca, and PhRMA challenging Maryland's H.B. 1056, which restricts 340B drug manufacturers from limiting distribution of 340B drugs to contract pharmacies. The appellate court reversed the district court's finding that manufacturers were unlikely to succeed on federal preemption grounds.

Interleukin-17 Inhibitors Patent - Novartis AG

The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.

LAG-3 Antibody Combination Therapies - Patent US12600777B2

The USPTO granted patent US12600777B2 to Novartis AG covering combination therapies comprising antibody molecules that specifically bind to LAG-3. The patent contains seven claims and relates to methods for treating, preventing, and/or diagnosing cancerous or infectious disorders. This represents a grant of exclusive intellectual property rights to Novartis AG for the therapeutic application of LAG-3 antibody combinations.

Trump Administration Imposes 100% Pharmaceutical Tariffs and Restructures Metals Tariffs Under Section 232

On April 2, 2026, President Trump signed two presidential proclamations under Section 232 imposing a 100 percent ad valorem duty on imports of patented pharmaceuticals and pharmaceutical ingredients, effective July 31, 2026. Annex III lists 17 major pharmaceutical companies including AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi. A concurrent metals proclamation restructured tariffs on aluminum, steel, and copper articles to a 50 percent ad valorem rate on full customs value, effective April 6, 2026, replacing the prior ad valorem-plus-specific-rate calculation methodology.

State AG Settlements and Lawsuit Over Generic Drug Prices

South Dakota Attorney General Marty Jackley announced settlements totaling $17.85 million with Lannett Company and Bausch Health over alleged price inflation of generic drugs. Additionally, the state joined a lawsuit against Novartis and Sandoz for similar price-fixing allegations.

IL-17 antagonist compositions for treating inflammatory arthritis

USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.

Methods of treating psoriasis with secukinumab

The USPTO granted patent US12594332B2 to Novartis AG covering novel regimens for treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent includes 11 claims directed to therapeutic methods employing the antibody. The patent application was filed on December 16, 2024, with inventors including Achim Guettner, Matthias Machacek, Charis Papavassilis, and Oliver Sander.

TREM2 stabilizing antibodies, Novartis AG, patent grant

The USPTO granted Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein. The patent names nine inventors and includes 10 claims, establishing Novartis's exclusive rights to this antibody technology.

Bispecific CAR Targeting CD19 and CD20 for Cancer Treatment

USPTO granted Patent US12594321B2 to Novartis AG for a bispecific chimeric antigen receptor (CAR) targeting CD19 and CD20 for cancer treatment. The patent covers CAR proteins, encoding nucleic acids, vectors, and methods for treating diseases associated with CD20 or CD22 expression using modified T or NK cells. The patent includes 18 claims and lists 6 inventors.

State AGs Settle with Lannett and Bausch for $17.85M Over Price Fixing

State Attorneys General, led by Connecticut AG William Tong, have settled with Lannett Company and Bausch Health for $17.85 million over allegations of price fixing and limiting competition for generic prescription drugs. The settlements include cooperation in ongoing litigation and internal reforms. A new lawsuit was also filed against Novartis and its subsidiaries.

State AGs Announce $17.85M Drug Price Fixing Settlements

A multistate coalition of 48 states and territories, led by Attorney General Phil Weiser, announced settlements totaling $17.85 million with Lannett Company and Bausch Health over allegations of drug price fixing. The settlements require cooperation with ongoing litigation and internal reforms. A new lawsuit was also filed against Novartis and Sandoz.

State AGs Secure $17.85M Settlements in Drug Price-Fixing Conspiracy

Attorneys General from 48 states and territories announced $17.85 million in settlements with Lannett Company and Bausch Health for alleged drug price-fixing conspiracies. The settlements resolve allegations of artificially inflating prices for generic prescription drugs and require internal reforms. A new complaint was also filed against Novartis and Sandoz.

State AGs Secure $17.85M Settlements with Pharma Companies, File New Complaint

Massachusetts Attorney General Andrea Joy Campbell, joined by 48 other states and territories, secured $17.85 million in settlements with Lannett and Bausch over price manipulation schemes for generic drugs. A new lawsuit was also filed against Novartis and Sandoz for similar allegations. Massachusetts will receive $203,410 from the settlements.

State AGs Announce Pharmaceutical Settlements and Lawsuit

Multiple State Attorneys General announced settlements totaling $17.85 million with Lannett and Bausch for alleged price inflation conspiracies. Additionally, a coalition of states filed a new lawsuit against Novartis for similar allegations and asset manipulation. These actions aim to hold pharmaceutical companies accountable and recover funds for consumers.

Kisqali Tablets: Updated Storage Conditions and Shelf Life

Novartis Pharma GmbH has updated the storage conditions and shelf life for Kisqali 200 mg film-coated tablets. The medicine no longer requires refrigeration and now has an authorized shelf life of 2 years. This information letter was issued by the BfArM.